Home Newsfeeds Susquehanna Maintains Neutral on TransDigm Gr, Raises Price Target to $750

Susquehanna Maintains Neutral on TransDigm Gr, Raises Price Target to $750

Susquehanna analyst Charles Minervino maintains TransDigm Gr (NYSE:TDG) with a Neutral and raises the price target from $665 to $750.

byBenzinga Newsdesk

February 8, 2023

1 minute read

Susquehanna analyst Charles Minervino maintains TransDigm Gr (NYSE:TDG) with a Neutral and raises the price target from $665 to $750.

Morgan Stanley Maintains Overweight on National Instruments, Raises Price Target to $49

By Benzinga Newsdesk

October 11, 10:55 AM

Morgan Stanley analyst Meta Marshall maintains National Instruments (NASDAQ:NATI) with a Overweight and raises the price target from $46 to $49.

NATI

Analyst Ratings

Wells Fargo Maintains Overweight Rating for Tractor Supply: Here’s What You Need To Know

By Benzinga Insights

July 18, 1:00 PM

Wells Fargo has decided to maintain its Overweight rating of Tractor Supply (NASDAQ:TSCO) and lower its price target…

TSCO

Vertex’s Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs

By Vandana Singh

February 6, 3:55 PM

Vertex Pharmaceuticals' cystic fibrosis treatment with vanza triple therapy. SKYLINE trials show non-inferiority to Trikafta, emphasizing once-daily dosing benefits.

VRTX

Barclays Maintains Underweight on Clorox, Raises Price Target to $101

By Benzinga Newsdesk

August 19, 7:05 AM

Barclays analyst Lauren Lieberman maintains Clorox (NYSE:CLX) with a Underweight and raises the price target from $93 to $101.

CLX

Susquehanna Maintains Neutral on TransDigm Gr, Raises Price Target to $750

Related Posts

Morgan Stanley Maintains Overweight on National Instruments, Raises Price Target to $49

Wells Fargo Maintains Overweight Rating for Tractor Supply: Here’s What You Need To Know

Vertex’s Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs

Barclays Maintains Underweight on Clorox, Raises Price Target to $101